{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:43Z","timestamp":1793272783200,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bmcl.2022.128951","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:30:46Z","timestamp":1661628646000},"page":"128951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer"],"prefix":"10.1016","volume":"75","author":[{"given":"Chetan","family":"Padmakar Darne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upender","family":"Velaparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Frennesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audris","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tokarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aberra","family":"Fura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Newitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Obermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Elzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco M.","family":"Gottardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lata","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Vite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Balog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128951_b0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2022.128951_b0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4103\/1008-682X.129133","article-title":"Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer","volume":"16","author":"Stein","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.bmcl.2022.128951_b0015","first-page":"232","article-title":"Studies on prostatic cancer i. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7150\/ijbs.14090","article-title":"Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer","volume":"12","author":"Wadosky","year":"2016","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.bmcl.2022.128951_b0025","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","article-title":"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer","volume":"167","author":"Tratchenberg","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2008.05.045","article-title":"Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade","volume":"180","author":"Suzuki","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0035","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0040","doi-asserted-by":"crossref","unstructured":"Blass BE, Iyer P, Abou-Gharbia M et al. Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17\u03b1-hydroxylase-C17,20-lyase (Cyp17). Bioorg Med Chem Lett. 2018; 28: 2270-2274.","DOI":"10.1016\/j.bmcl.2018.05.040"},{"key":"10.1016\/j.bmcl.2022.128951_b0045","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-10-0255","article-title":"Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer","volume":"16","author":"Yamaoka","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2022.128951_b0055","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1078-0432.CCR-11-1805","article-title":"Abiraterone in Prostate Cancer: A new angle to an old problem","volume":"18","author":"Stein","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17. Established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128951_b0065","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer","volume":"168","author":"Harris","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/13543784.2016.1162784","article-title":"Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer","volume":"25","author":"Dellis","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmcl.2022.128951_b0075","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abirateron and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2022.128951_b0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2017.03.037","article-title":"Discovery of novel 1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c] pyridine derivatives as potent and selective CYP17 inhibitors","volume":"132","author":"Wang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0085","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bmcl.2022.128951_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2011.275","article-title":"Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor","volume":"91","author":"Bryce","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2022.128951_b0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2310\/JIM.0b013e3182408567","article-title":"Human Steroid Biosynthesis for the Oncologist","volume":"60","author":"Auchus","year":"2012","journal-title":"J Invest Med"},{"key":"10.1016\/j.bmcl.2022.128951_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.bmcl.2022.128951_b0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5489\/cuaj.2526","article-title":"The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)","volume":"9","author":"Saad","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.bmcl.2022.128951_b0115","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/cancers11111637","article-title":"Galeterone and the next generation Galeterone analogs, VNPP414 and VNPP433-3\u03b2 exert potent therapeutic effects in castration-\/drug-resistant prostate cancer preclinical models in vitro and in vivo","volume":"11","author":"Kwegyir-Afful","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2022.128951_b0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 Inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Yin","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2011.04.032","article-title":"The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature","volume":"60","author":"Sonpavde","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol & Metab"},{"key":"10.1016\/j.bmcl.2022.128951_b0135","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Trans Androl Urol"},{"key":"10.1016\/j.bmcl.2022.128951_b0140","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","article-title":"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","volume":"19","author":"Kaku","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0145","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.euf.2016.10.008","article-title":"Optimal treatment sequence for metastatic castration-resistant prostate cancer","volume":"2","author":"Lorente","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.bmcl.2022.128951_b0150","doi-asserted-by":"crossref","unstructured":"Petrunak EM, Rogers SA, Aub\u00e9 J, Scott EM. Structural and functional evaluation of clinically relevant inhibitors of steroidogenic cytochrome P450 17A1. Drug Metab Dispos. 2017; 45:635-645.","DOI":"10.1124\/dmd.117.075317"},{"key":"10.1016\/j.bmcl.2022.128951_b0155","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1078-0432.CCR-15-1432","article-title":"Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: Galeterone for the treatment of castration-resistant prostate cancer","volume":"22","author":"Montgomery","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128951_b0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"Fizazi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2022.128951_b0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bmcl.2022.128951_b0170","unstructured":"www.laeknatp.com."},{"key":"10.1016\/j.bmcl.2022.128951_b0175","doi-asserted-by":"crossref","unstructured":"Garcia JA, Dreicer R, Pantuck AJ, Haas NB, Vaishampayan UN et al. Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC). Clin Oncol. 2017; 35(6); 240-240.","DOI":"10.1200\/JCO.2017.35.6_suppl.240"},{"key":"10.1016\/j.bmcl.2022.128951_b0180","unstructured":"Smith RA, Laping NJ, Gupta S. Steroid-free disease management of prostate cancer using 1- (2- (4-fluorophenylthiazol-5-yl) 1- (pyridin-4-yl) ethanol (ASN001). PCT Int. Appl.2016;WO 2016018380 A1."},{"key":"10.1016\/j.bmcl.2022.128951_b0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/acsmedchemlett.5b00310","article-title":"Discovery of the selective CYP17A1 lyase inhibitor BMS-351 for the treatment of prostate cancer","volume":"7","author":"Huang","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128951_b0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2017.03.037","article-title":"Discovery of novel 1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine derivatives as potent and selective CYP17 inhibitors","volume":"132","author":"Wang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0195","first-page":"597","article-title":"CYP17 Inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling. Arch Pharm Chem","volume":"341","author":"Pinto-Bazurco Mendieta","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2022.128951_b0200","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.ejmech.2009.01.002","article-title":"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls","volume":"44","author":"Hille","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0205","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1021\/jm100317b","article-title":"Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17\/CYP11B1 inhibitors for the treatment of prostate cancer","volume":"53","author":"Hu","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0210","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1021\/jm100400a","article-title":"Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors","volume":"53","author":"Hu","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0215","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1021\/jm400484p","article-title":"Highly potent and selective nonsteroidal dual inhibitors of CYP17\/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases","volume":"56","author":"Mendieta","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejmech.2013.10.038","article-title":"An efficient approach to novel 17\u20135\u2019-(1\u2019,2\u2019,4\u2019)-oxadiazolyl androstenes via the cyclodehydration of cytotoxic O-steroidacylamidoximes, and an evaluation of their inhibitory action on 17\u03b1-hydroxylase\/C17,20-lyase","volume":"70","author":"Kov\u00e1cs","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0225","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejmech.2016.05.006","article-title":"Synthesis of novel 17-(4\u2019-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17\u03b1-hydroxylase\/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring","volume":"120","author":"Kov\u00e1cs","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0230","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1039\/C6CC08680B","article-title":"Structure-based optimization of non-steroidal cytochrome P450 17A1 inhibitors","volume":"53","author":"Larsen","year":"2017","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmcl.2022.128951_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103462","article-title":"Prospective computational design an in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors","volume":"94","author":"Gumede","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2022.128951_b0240","doi-asserted-by":"crossref","first-page":"29468","DOI":"10.1038\/srep29468","article-title":"Promising tools in prostate cancer research: selective non-steroidal cytochrome P45017A1 inhibitors","volume":"6","author":"Bonomo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2022.128951_b0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmb.2008.03.065","article-title":"Structural analysis of CYP2R1 in complex vitamin D3","volume":"380","author":"Strushkevich","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2022.128951_b0250","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"DeVore","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128951_b0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomologus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:09Z","timestamp":1760773569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"alternative-id":["S0960894X22004279"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128951","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128951"}}